MedImmune: Vaccine ready to go at month's end

MedImmune, which began clinical trials for its swine flu vaccine last month, says the inhaled vaccine could be ready by the end of September. The AstraZeneca subsidiary is now waiting on the FDA to review its safety data. "There are no red flags there," Dr. Raburn Mallory told Reuters. "We think we can have 5 million doses ready to distribute at the end of September." Once it gets the greenlight, MedImmune says it will begin shipping the nasal spray vaccine to the U.S. government to fulfill its $90 million contract. Article

Suggested Articles

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.

AZ is among the companies leading the COVID-19 vaccine race, and after agreeing first to supply the U.K., it's now in talks for delivery worldwide.